B. Blasio

Tamoxifen for early breast cancer: an overview of the randomised trials

Mike Clarke, Luc Bijnens, Michael Gnant, 1998, The Lancet.

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

Y Wang, Mike Clarke, Donald A. Berry, 2005, The Lancet.

Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.

Terry L. Smith, R. Collins, L. Holmberg, 1998, Lancet.

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

Ivanov, Harris, R. Collins, 2005, The Lancet.

Health budgetary allocation in BRIC countries: has their economic boom contributed to an improvement in the qualityof human life?

B. Blasio, 2012 .

Three new active cisplatin‐containing combinations in the neoadjuvant treatment of locally advanced and locally recurrent breast carcinoma: a randomized phase II trial

C. Boni, P. Morandi, G. Cocconi, 1999, Breast Cancer Research and Treatment.

Randomized trial comparing cyclophosphamide, methotrexate, and 5–fluorouracil (CMF) with rotational CMF, epirubicin and vincristine as primary chemotherapy in operable breast carcinoma

C. Boni, P. Bruzzi, G. Cocconi, 2002, Cancer.

Problems in evaluating response of primary breast cancer to systemic therapy

G. Cocconi, B. Blasio, G. Bisagni, 2005, Breast Cancer Research and Treatment.

Primary chemotherapy in operable breast carcinoma comparing CMF (cyclophosphamide, methotrexate, 5-fluorouracil) with an anthracycline-containing regimen: short-term responses translated into long-term outcomes.

C. Boni, P. Bruzzi, G. Cocconi, 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase II, randomized trial of preoperative epirubicin-paclitaxel +/− gefitinib with biomarker evaluation in operable breast cancer

C. Boni, A. Santoro, G. Banna, 2008, Breast Cancer Research and Treatment.